FDA panel votes 3-14 that Abbott (ABT) has not found right Humira dose
- Apple, Inc. (AAPL) Tops Q2 EPS by $1.44; Announces 7-for-1 Stock Split
- Zimmer (ZMH) to Acquire Biomet in ~$13.35B Deal
- UPS (UPS) Misses Q1 EPS by 10c; Sees FY14 EPS at Low-End of Range
- Herbalife (HLF) Questions Ackman's Campaign Following ABC News Report
- Caterpillar, Inc. (CAT) Tops Q1 EPS Views; Boosts FY14 Profit Outlook
FDA panel votes 3-14 that Abbott (NYSE: ABT) has not found right Humira dose.
You May Also Be Interested In
- Zogenix, Inc. (ZGNX) Will Sell SUMAVEL DosePro in $105M Deal with Endo (ENDP)
- Berkshire Hathaway's (BRK-A) BNSF reports train derailment at Cliff, Cali. - Bloomberg
- Alexion Pharmaceuticals, Inc. (ALXN) Initiates Soliris Safety, Efficacy Trial
Create E-mail Alert Related CategoriesFDA, General News
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!